好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Perivascular Tau in Autopsy Cases with Definite Cerebral Amyloid Angiopathy
Aging, Dementia, and Behavioral Neurology
P10 - Poster Session 10 (5:00 PM-6:00 PM)
3-007

The main aims of this study were to quantify the burden of tau-pathology in an autopsy cohort of clinical cases with cerebral amyloid angiopathy (CAA) and to characterize the presence of perivascular tau (PVT) accumulation and its relationship with CAA.  

CAA and Alzheimer's Disease Neuropathological Changes, such as tau-tangles, often coexist. The role of tau pathology in the pathophysiology of CAA remains to be determined.

Autopsy cases with a neuropathologically confirmed clinical diagnosis of CAA were evaluated. Samples were taken from cortical areas and underwent immunohistochemistry against amyloid-β (Aβ) and phosphorylated tau (At8). Deep-learning based models were created and applied to the samples to quantify 1) density of intraneuronal tau-tangles; 2) percentage area of cortical CAA and Aβ-plaques using the Aiforia® platform; 3) percentage area of total cortical tau-burden, using QuPath. Linear-mixed effects models were applied to assess the association between tau and CAA burden. The presence of dyshoric CAA (flamelike Aβ deposits that radiate into the perivascular neuropil), and PVT (accentuated accumulation of tau around the vessel) were visually identified on Aβ vs. At8-stained sections respectively. Single-vessel analysis was performed to determine whether there was an association between PVT and CAA using Chi-square tests. 

A total of 76 sections in 19 CAA cases (median age-at-death 76 years [64–88]; 7 females) were analyzed. Higher tau-tangles and total tau-burden were observed in the temporal cortex versus the occipital cortex (p=0.05). CAA burden was not associated with tau-tangles or total tau-burden. Dyshoric CAA was observed around at least one vessel in 71 (93.4%) of the sections and PVT in 32 (34%) of the sections. In single-vessel analysis, PVT was significantly associated with both dyshoric CAA (p=0.004) and any CAA (p=0.0005).

Tau was not regionally associated with CAA in this autopsy-cohort. Accumulation of PVT was significantly associated with CAA in the single-vessel analysis.
Authors/Disclosures
Suzete N. Farias Da Guarda, MD, PhD (Massachusetts General Hospital)
PRESENTER
Prof. Farias Da Guarda has nothing to disclose.
Kali vom Eigen, BA Ms. vom Eigen has nothing to disclose.
Thijs W. van Harten, PhD Dr. van Harten has nothing to disclose.
Corinne Auger Ms. Auger has nothing to disclose.
Steven M. Greenberg, MD, PhD, FAAN Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squib. The institution of Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Greenberg has received research support from National Institutes of Health. Dr. Greenberg has received publishing royalties from a publication relating to health care.
Anand Viswanathan, MD (Massachusetts General Hospital) Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam Pharmaceuticals. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharmaceuticals.
Susanne J. van Veluw, PhD Dr. van Veluw has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. The institution of Dr. van Veluw has received research support from NIH. The institution of Dr. van Veluw has received research support from Sanofi. The institution of Dr. van Veluw has received research support from Leducq Foundation. The institution of Dr. van Veluw has received research support from American Heart Association. The institution of Dr. van Veluw has received research support from Frechette Family Foundation. The institution of Dr. van Veluw has received research support from BrightFocus Foundation. The institution of Dr. van Veluw has received research support from Therini Bio.
Valentina Perosa, MD (MGH/HMS) Dr. Perosa has nothing to disclose.